Adjuvant Therapy Trials.

Area of Science:

• Oncology
• Gastrointestinal Oncology
• Cancer Therapeutics

Background:

• Recent approvals of ramucirumab and TAS-102 mark advancements in colorectal cancer treatment.
• However, adjuvant treatment options for stages II and III colon cancer have seen minimal progress, with only three established agents available.
• The field faces a decade-long stagnation in novel adjuvant therapies for early-stage colon cancer.

Purpose of the Study:

• To analyze the historical progression and current state of adjuvant therapies for stages II and III colon cancer.
• To critically evaluate the reasons behind the lack of new drug additions to the adjuvant colon cancer treatment armamentarium.
• To explore potential strategies and future directions for advancing colon cancer adjuvant therapy.

Main Methods:

• Review of Food and Drug Administration (FDA) drug approvals for colorectal cancer.
• Analysis of clinical trial data and treatment guidelines for colon cancer.
• Examination of research trends and unmet needs in adjuvant colon cancer therapy.

Main Results:

• Despite numerous approvals for advanced colorectal cancer, only 5-fluorouracil, capecitabine, and oxaliplatin remain effective in adjuvant settings.
• No new agents have been successfully added to the adjuvant therapy for stages II and III colon cancer in over ten years.
• Levamisole, previously used, has been subtracted from the standard adjuvant treatment options.

Conclusions:

• The current landscape of adjuvant colon cancer therapy is characterized by a significant lack of innovation and progress.
• Understanding the barriers to developing new adjuvant treatments is crucial for future research.
• A concerted effort is needed to identify and validate novel therapeutic strategies to improve outcomes for early-stage colon cancer patients.